1
|
Liao W, Du H, Chen M, Xiong Y, Zhou H, Qin T, Liu B. Sequential regioselective arylation of pyrazolones with diaryliodonium salts. Org Biomol Chem 2024; 22:708-713. [PMID: 38165289 DOI: 10.1039/d3ob01854g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2024]
Abstract
The introduction of aromatic substituents into organic compounds significantly alters their physical and chemical characteristics. Yet, achieving precise control over the site-selectivity of arylation continues to pose a considerable challenge. We present here a controllable method for the site-selective mono-, di-, and triarylation of pyrazolone with diaryliodonium salts. The method showcases robustness, flexibility, and excellent compatibility with a broad range of functional groups. It enables control over both the site of arylation and the number of aryl additions. Specifically, three of the four substitutable positions in pyrazolone can be selectively arylated, effectively producing four products under controlled conditions. Additionally, the method supports one-pot sequential arylation, leading to an array of products with diverse aromatic substituents. Control experiments revealed the specific conditions of each reaction step.
Collapse
Affiliation(s)
- Wenbo Liao
- College of Materials and Chemical Engineering, Key Laboratory of Inorganic Nonmetallic Crystalline and Energy Conversion Materials, China Three Gorges University, Yichang, Hubei 443002, PR China.
| | - Hairui Du
- College of Materials and Chemical Engineering, Key Laboratory of Inorganic Nonmetallic Crystalline and Energy Conversion Materials, China Three Gorges University, Yichang, Hubei 443002, PR China.
| | - Mingxiu Chen
- College of Materials and Chemical Engineering, Key Laboratory of Inorganic Nonmetallic Crystalline and Energy Conversion Materials, China Three Gorges University, Yichang, Hubei 443002, PR China.
| | - Yan Xiong
- College of Materials and Chemical Engineering, Key Laboratory of Inorganic Nonmetallic Crystalline and Energy Conversion Materials, China Three Gorges University, Yichang, Hubei 443002, PR China.
| | - Heye Zhou
- College of Materials and Chemical Engineering, Key Laboratory of Inorganic Nonmetallic Crystalline and Energy Conversion Materials, China Three Gorges University, Yichang, Hubei 443002, PR China.
| | - Tao Qin
- College of Materials and Chemical Engineering, Key Laboratory of Inorganic Nonmetallic Crystalline and Energy Conversion Materials, China Three Gorges University, Yichang, Hubei 443002, PR China.
| | - Bin Liu
- College of Materials and Chemical Engineering, Key Laboratory of Inorganic Nonmetallic Crystalline and Energy Conversion Materials, China Three Gorges University, Yichang, Hubei 443002, PR China.
| |
Collapse
|
2
|
Ma BB, Montgomery AP, Chen B, Kassiou M, Danon JJ. Strategies for targeting the P2Y 12 receptor in the central nervous system. Bioorg Med Chem Lett 2022; 71:128837. [PMID: 35640763 DOI: 10.1016/j.bmcl.2022.128837] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 05/10/2022] [Accepted: 05/26/2022] [Indexed: 11/28/2022]
Abstract
The purinergic 2Y type 12 receptor (P2Y12R) is a well-known biological target for anti-thrombotic drugs due to its role in platelet aggregation and blood clotting. While the importance of the P2Y12R in the periphery has been known for decades, much less is known about its expression and roles in the central nervous system (CNS), where it is expressed exclusively on microglia - the first responders to brain insults and neurodegeneration. Several seminal studies have shown that P2Y12 is a robust, translatable biomarker for anti-inflammatory and neuroprotective microglial phenotypes in models of degenerative diseases such as multiple sclerosis and Alzheimer's disease. An enduring problem for studying this receptor in vivo, however, is the lack of selective, high-affinity small molecule ligands that can bypass the blood-brain barrier and accumulate in the CNS. In this Digest, we discuss previous attempts by researchers to target the P2Y12R in the CNS and opine on strategies that may be employed to design and assess the suitability of novel P2Y12 ligands for this purpose going forward.
Collapse
Affiliation(s)
- Ben B Ma
- School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia
| | | | - Biling Chen
- School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia
| | - Michael Kassiou
- School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia
| | - Jonathan J Danon
- School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
| |
Collapse
|
3
|
Müller CE, Namasivayam V. Recommended tool compounds and drugs for blocking P2X and P2Y receptors. Purinergic Signal 2021; 17:633-648. [PMID: 34476721 PMCID: PMC8677864 DOI: 10.1007/s11302-021-09813-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 07/15/2021] [Indexed: 12/21/2022] Open
Abstract
This review article presents a collection of tool compounds that selectively block and are recommended for studying P2Y and P2X receptor subtypes, investigating their roles in physiology and validating them as future drug targets. Moreover, drug candidates and approved drugs for P2 receptors will be discussed.
Collapse
Affiliation(s)
- Christa E Müller
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
| | - Vigneshwaran Namasivayam
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany
| |
Collapse
|
4
|
Yuan Y, Li LS, Zhang L, Wang F, Jiang L, Zuo L, Wang Q, Hu JG, Lei A. Electrochemical synthesis of versatile ammonium oxides under metal catalyst-, exogenous-oxidant-, and exogenous-electrolyte-free conditions. Chem Commun (Camb) 2021; 57:2768-2771. [PMID: 33596296 DOI: 10.1039/d1cc00486g] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
An electrochemical oxidative cross-coupling reaction between 2.5-substituted-pyrazolin-5-ones and ammonium thiocyanate has been developed, which resulted in a series of unprecedented cross-coupling products under metal catalyst-, exogenous-oxidant-, and exogenous-electrolyte-free conditions. It is worth noting that since the resulting cross-coupling products are nearly insoluble in MeCN, the pure product could be afforded without silica gel column purification. In addition, the prepared ammonium oxides are versatile building blocks for synthesizing functionalized pyrazole derivatives.
Collapse
Affiliation(s)
- Yong Yuan
- National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, P. R. China. and Gansu International Scientific and Technological Cooperation Base of Water-Retention Chemical Functional Materials, College of Chemistry and Chemical Engineering, Northwest Normal University, Lanzhou, Gansu 730070, China
| | - Liang-Sen Li
- National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, P. R. China.
| | - Lin Zhang
- National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, P. R. China.
| | - Feng Wang
- National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, P. R. China.
| | - Lin Jiang
- National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, P. R. China.
| | - Lin Zuo
- National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, P. R. China.
| | - Qi Wang
- National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, P. R. China.
| | - Jian-Guo Hu
- National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, P. R. China.
| | - Aiwen Lei
- National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, P. R. China. and College of Chemistry and Molecular Sciences, Institute for Advanced Studies (IAS), Wuhan University, Wuhan 430072, P. R. China
| |
Collapse
|
5
|
Molecular pharmacology of P2Y receptor subtypes. Biochem Pharmacol 2020; 187:114361. [PMID: 33309519 DOI: 10.1016/j.bcp.2020.114361] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Revised: 12/06/2020] [Accepted: 12/07/2020] [Indexed: 02/06/2023]
Abstract
Professor Geoffrey Burnstock proposed the concept of purinergic signaling via P1 and P2 receptors. P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular adenine and uracil nucleotides. Eight mammalian P2Y receptor subtypes have been identified. They are divided into two subgroups (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) and (P2Y12, P2Y13, and P2Y14). P2Y receptors are found in almost all cells and mediate responses in physiology and pathophysiology including pain and inflammation. The antagonism of platelet P2Y12 receptors by cangrelor, ticagrelor or active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel reduces the ADP-induced platelet aggregation in patients with thrombotic complications of vascular diseases. The nucleotide agonist diquafosol acting at P2Y2 receptors is used for the treatment of the dry eye syndrome. Structural information obtained by crystallography of the human P2Y1 and P2Y12 receptor proteins, site-directed mutagenesis and molecular modeling will facilitate the rational design of novel selective drugs.
Collapse
|
6
|
Popa MM, Shova S, Hrubaru M, Barbu L, Draghici C, Dumitrascu F, Dumitrescu DE. Introducing chirality in halogenated 3-arylsydnones and their corresponding 1-arylpyrazoles obtained by 1,3-dipolar cycloaddition. RSC Adv 2020; 10:15656-15664. [PMID: 35493656 PMCID: PMC9052417 DOI: 10.1039/d0ra02368j] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Accepted: 04/11/2020] [Indexed: 12/15/2022] Open
Abstract
New 1-arylpyrazoles substituted with halogen atoms (Br, I) were synthesized from the corresponding sydnones by 1,3-dipolar cycloaddition. By introduction of a prochiral group such as isopropyl, in the ortho position of the benzene ring, in the starting phenylglycine 1 the rotamers caused by the hindered rotation between the phenyl and the heterocyclic ring were detected by NMR spectroscopy for 1-arylpyrazoles and for the first time for 3-arylsydnones. The N-nitrosophenylglycines present E–Z stereoisomerism due to the partial C–N double bond character. All the new compounds were structurally characterized by NMR spectroscopy and confirmed by X-ray crystallography. The crystal structures of N-nitrosophenylglycine 2c and of the sydnone 3c present similar Br⋯Br type II halogen contacts. New 1-arylpyrazoles substituted with halogen atoms (Br, I) were synthesized from the corresponding sydnones by 1,3-dipolar cycloaddition.![]()
Collapse
Affiliation(s)
- Marcel Mirel Popa
- Center of Organic Chemistry “C. D. Nenitzescu”
- Romanian Academy
- 060023 Bucharest
- Romania
| | - Sergiu Shova
- “Petru Poni” Institute of Macromolecular Chemistry
- Iasi 700487
- Romania
| | - Madalina Hrubaru
- Center of Organic Chemistry “C. D. Nenitzescu”
- Romanian Academy
- 060023 Bucharest
- Romania
| | - Loredana Barbu
- Center of Organic Chemistry “C. D. Nenitzescu”
- Romanian Academy
- 060023 Bucharest
- Romania
| | - Constantin Draghici
- Center of Organic Chemistry “C. D. Nenitzescu”
- Romanian Academy
- 060023 Bucharest
- Romania
| | - Florea Dumitrascu
- Center of Organic Chemistry “C. D. Nenitzescu”
- Romanian Academy
- 060023 Bucharest
- Romania
| | | |
Collapse
|
7
|
Cacciari B, Crepaldi P, Cheng CY, Bossi E, Spalluto G, Federico S, Jacobson KA, Cattaneo M. Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors. Med Chem 2019; 15:863-872. [PMID: 30734681 DOI: 10.2174/1573406415666190208124534] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Revised: 12/16/2018] [Accepted: 12/18/2018] [Indexed: 12/15/2022]
Abstract
BACKGROUND Platelet aggregation plays a pathogenic role in the development of arterial thrombi, which are responsible for common diseases caused by thrombotic arterial occlusion, such as myocardial infarction and stroke. Much efforts are directed toward developing platelet aggregation inhibitors that act through several mechanisms: The main antiplatelet family of COXinhibitors, phosphodiesterase inhibitors, and thrombin inhibitors. Recently, the important role in the platelet aggregation of adenosine diphosphate (ADP)-activated P2Y12 and P2Y1 receptors, Gprotein coupled receptors of the P2 purinergic family, has emerged, and their inhibitors are explored as potential therapeutic antithrombotics. P2Y12 inhibitors, i.e. clopidogrel, prasugrel, ticagrelor, and cangrelor, are already used clinically to reduce coronary artery thrombosis risk and prevent acute coronary syndromes. The search for new P2Y12 inhibitors, with better risk-to-benefit profiles is still ongoing. METHODS Several years ago, our group prepared a series of 6-amino-2-thio-3H-pyrimidin-4-one derivatives that displayed an interesting platelet aggregation inhibiting activity. In order to probe the structure-activity relationships and improve their inhibitory effects of these compounds, we synthesized variously substituted 6-amino-2-thio-3H-pyrimidin-4-one derivatives and substituted 4-amino-2-thiopyrimidine-5-carboxylic acid analogues. All the synthesized compounds were tested by light trasmission aggregometry (LTA) as inducers or inhibitors of platelet aggregation in citrated platelet-rich plasma (PRP). RESULTS Among the 6-amino-2-thio-3H-pyrimidin-4-one derivatives, compounds 2c and 2h displayed marked inhibitory activity, with a capability to inhibit the ADP(10-6M)-induced platelet aggregation by 91% and 87% at 10-4M concentration, respectively. Selected 4-amino-2- thiopyrimidine-5-carboxylic acid derivatives were tested as P2Y12 and P2Y1 antagonists and found to display negligible activity. CONCLUSION These negative findings demonstrated that this heterocyclic nucleus is not a useful common pharmacophore for developing P2Y-dependent inhibitors of platelet aggregation. Nevertheless, compounds 2c and 2h could represent a new chemotype to further develop inhibitors of platelet aggregation.
Collapse
Affiliation(s)
- Barbara Cacciari
- Dipartimento di Scienze Chimiche e Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44121 Ferrara, Italy
| | - Pamela Crepaldi
- Dipartimento di Scienze Chimiche e Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44121 Ferrara, Italy
| | - Chun Yan Cheng
- Unità di Medicina III, Azienda Ospedaliera San Paolo, Dipartimento di Scienze della Salute, Università di Milano, Via di Rudinì 8, I-20142 Milano, Italy
| | - Elena Bossi
- Unità di Medicina III, Azienda Ospedaliera San Paolo, Dipartimento di Scienze della Salute, Università di Milano, Via di Rudinì 8, I-20142 Milano, Italy
| | - Giampiero Spalluto
- Dipartimento di Scienze Cimiche e Farmaceutiche, Università di Trieste, Piazzale europa 1, I-34127 Trieste, Italy
| | - Stephanie Federico
- Dipartimento di Scienze Cimiche e Farmaceutiche, Università di Trieste, Piazzale europa 1, I-34127 Trieste, Italy
| | - Kenneth A Jacobson
- Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, United States
| | - Marco Cattaneo
- Unità di Medicina III, Azienda Ospedaliera San Paolo, Dipartimento di Scienze della Salute, Università di Milano, Via di Rudinì 8, I-20142 Milano, Italy
| |
Collapse
|
8
|
von Kügelgen I. Pharmacology of P2Y receptors. Brain Res Bull 2019; 151:12-24. [PMID: 30922852 DOI: 10.1016/j.brainresbull.2019.03.010] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 03/04/2019] [Accepted: 03/17/2019] [Indexed: 01/17/2023]
Abstract
P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides. There are eight mammalian P2Y receptor subtypes divided into two subgroups (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) and (P2Y12, P2Y13, and P2Y14). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain. The antagonism of P2Y12 receptors is used in pharmacotherapy for the prevention and therapy of cardiovascular events. The nucleoside analogue ticagrelor and active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel inhibit platelet P2Y12 receptors and reduce thereby platelet aggregation. The P2Y2 receptor agonist diquafosol is used for the treatment of the dry eye syndrome. The P2Y receptor subtypes differ in their amino acid sequences, their pharmacological profiles and their signaling transduction pathways. Recently, selective receptor ligands have been developed for all subtypes. The published crystal structures of the human P2Y1 and P2Y12 receptors as well as receptor models will facilitate the development of novel drugs for pharmacotherapy.
Collapse
Affiliation(s)
- Ivar von Kügelgen
- Department of Pharmacology and Toxicology, Pharma Center, University of Bonn, D-53127, Bonn, Germany.
| |
Collapse
|
9
|
von Kügelgen I. Structure, Pharmacology and Roles in Physiology of the P2Y 12 Receptor. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2018; 1051:123-138. [PMID: 28921447 DOI: 10.1007/5584_2017_98] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides. The platelet ADP-receptor which has been denominated P2Y12 receptor is an important target in pharmacotherapy. The receptor couples to Gαi2 mediating an inhibition of cyclic AMP accumulation and additional downstream events including the activation of phosphatidylinositol-3-kinase and Rap1b proteins. The nucleoside analogue ticagrelor and active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel block P2Y12 receptors and, thereby, inhibit ADP-induced platelet aggregation. These drugs are used for the prevention and therapy of cardiovascular events such as acute coronary syndromes or stroke. The recently published three-dimensional crystal structures of the human P2Y12 receptor in complex with agonists and antagonists will facilitate the development of novel therapeutic agents with reduced adverse effects. P2Y12 receptors are also expressed on vascular smooth muscle cells and may be involved in the pathophysiology of atherogenesis. P2Y12 receptors on microglial cells operate as sensors for adenine nucleotides released during brain injury. A recent study indicated the involvement of microglial P2Y12 receptors in the activity-dependent neuronal plasticity. Interestingly, there is evidence for changes in P2Y12 receptor expression in CNS pathologies including Alzheimer's diseases and multiple sclerosis. P2Y12 receptors may also be involved in systemic immune modulating responses and the susceptibility to develop bronchial asthma.
Collapse
Affiliation(s)
- Ivar von Kügelgen
- Department of Pharmacology and Toxicology, Pharma Center, University of Bonn, D-53127, Bonn, Germany.
| |
Collapse
|
10
|
Reversible, orally available ADP receptor (P2Y12) antagonists Part I: Hit to lead process. Bioorg Med Chem Lett 2018; 28:1459-1463. [DOI: 10.1016/j.bmcl.2018.03.090] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2018] [Revised: 03/26/2018] [Accepted: 03/30/2018] [Indexed: 11/19/2022]
|
11
|
Sharma A, Kishore D, Singh B. An Expedient Method for the Synthesis of 1,2,4-Triazolo-fused 1,5-Benzodiazepine, 1,5-Benzoxazepine, and 1,5-Benzothiazepine Scaffolds: A Novel Seven-membered Ring System of Biological Interest. J Heterocycl Chem 2018. [DOI: 10.1002/jhet.3060] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Aruna Sharma
- Department of Chemistry; JECRC University; Jaipur Rajasthan 303905 India
| | - Dharma Kishore
- Department of Chemistry; Banasthali Vidyapith; Banasthali Rajasthan 304022 India
| | - Bhawani Singh
- Department of Pure & Applied Chemistry; University of Kota; Kota Rajasthan 324005 India
| |
Collapse
|
12
|
Liu Q, Huang T, Zhao X, Wu J, Cao S. Bismuth(III)-Promoted Trifluoromethylthiolation of Pyrazolin-5-ones with Trifluoromethanesulfenamide. ACS OMEGA 2017; 2:7755-7759. [PMID: 31457332 PMCID: PMC6645000 DOI: 10.1021/acsomega.7b01453] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Accepted: 10/31/2017] [Indexed: 06/10/2023]
Abstract
An efficient and facile method for the synthesis of trifluoromethylthiolated 5-hydroxy-1H-pyrazole derivatives by reaction of pyrazolin-5-ones with trifluoromethanesulfenamide (PhNHSCF3) in the presence of BiCl3 was developed.
Collapse
Affiliation(s)
- Qingyun Liu
- Shanghai
Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology (ECUST), Shanghai 200237, China
| | - Tao Huang
- Shanghai
Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology (ECUST), Shanghai 200237, China
| | - Xianghu Zhao
- Shanghai
Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology (ECUST), Shanghai 200237, China
| | - Jingjing Wu
- School
of Chemical and Environmental Engineering, Shanghai Institute of Technology (SIT), Shanghai 201418, China
| | - Song Cao
- Shanghai
Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology (ECUST), Shanghai 200237, China
| |
Collapse
|
13
|
Vydzhak RN, Panchishin SY, Brovarets VS. Alkylation of 4-(phenylthio)-1H-pyrazol-5-ols with methyl bromoacetate. RUSS J GEN CHEM+ 2017. [DOI: 10.1134/s107036321702013x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
14
|
Conroy S, Kindon N, Kellam B, Stocks MJ. Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development. J Med Chem 2016; 59:9981-10005. [PMID: 27413802 DOI: 10.1021/acs.jmedchem.5b01972] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
P2Y receptors are expressed in virtually all cells and tissue types and mediate an astonishing array of biological functions, including platelet aggregation, smooth muscle cell proliferation, and immune regulation. The P2Y receptors belong to the G protein-coupled receptor superfamily and are composed of eight members encoded by distinct genes that can be subdivided into two groups on the basis of their coupling to specific G-proteins. Extensive research has been undertaken to find modulators of P2Y receptors, although to date only a limited number of small-molecule P2Y receptor antagonists have been approved by drug/medicines agencies. This Perspective reviews the known P2Y receptor antagonists, highlighting oral drug-like receptor antagonists, and considers future opportunities for the development of small molecules for clinical evaluation.
Collapse
Affiliation(s)
- Sean Conroy
- Centre for Biomolecular Sciences, University of Nottingham , University Park, Nottingham NG7 2RD, U.K
| | - Nicholas Kindon
- Centre for Biomolecular Sciences, University of Nottingham , University Park, Nottingham NG7 2RD, U.K
| | - Barrie Kellam
- Centre for Biomolecular Sciences, University of Nottingham , University Park, Nottingham NG7 2RD, U.K
| | - Michael J Stocks
- Centre for Biomolecular Sciences, University of Nottingham , University Park, Nottingham NG7 2RD, U.K
| |
Collapse
|
15
|
Zetterberg F, Svensson P. State of affairs: Design and structure–activity relationships of reversible P2Y 12 receptor antagonists. Bioorg Med Chem Lett 2016; 26:2739-2754. [DOI: 10.1016/j.bmcl.2016.04.030] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Revised: 04/10/2016] [Accepted: 04/12/2016] [Indexed: 12/13/2022]
|
16
|
Synthesis of fluorovinyl pyrazolyl (thio)ethers by the reaction of gem -difluoroalkenes with pyrazolin-5-ones (thiones). J Fluor Chem 2016. [DOI: 10.1016/j.jfluchem.2015.12.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
17
|
Caroff E, Hubler F, Meyer E, Renneberg D, Gnerre C, Treiber A, Rey M, Hess P, Steiner B, Hilpert K, Riederer MA. 4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. J Med Chem 2015; 58:9133-53. [DOI: 10.1021/acs.jmedchem.5b00933] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Eva Caroff
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Francis Hubler
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Emmanuel Meyer
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Dorte Renneberg
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Carmela Gnerre
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Alexander Treiber
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Markus Rey
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Patrick Hess
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Beat Steiner
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Kurt Hilpert
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Markus A. Riederer
- Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| |
Collapse
|
18
|
Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information. J Comput Aided Mol Des 2015. [PMID: 26194851 DOI: 10.1007/s10822-015-9858-z] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The G protein-coupled P2Y12 receptor (P2Y12R) is an important antithrombotic target and of great interest for pharmaceutical discovery. Its recently solved, highly divergent crystallographic structures in complex either with nucleotides (full or partial agonist) or with a nonnucleotide antagonist raise the question of which structure is more useful to understand ligand recognition. Therefore, we performed extensive molecular modeling studies based on these structures and mutagenesis, to predict the binding modes of major classes of P2Y12R ligands previously reported. Various nucleotide derivatives docked readily to the agonist-bound P2Y12R, but uncharged nucleotide-like antagonist ticagrelor required a hybrid receptor resembling the agonist-bound P2Y12R except for the top portion of TM6. Supervised molecular dynamics (SuMD) of ticagrelor binding indicated interactions with the extracellular regions of P2Y12R, defining possible meta-binding sites. Ureas, sulfonylureas, sulfonamides, anthraquinones and glutamic acid piperazines docked readily to the antagonist-bound P2Y12R. Docking dinucleotides at both agonist- and antagonist-bound structures suggested interactions with two P2Y12R pockets. Thus, our structure-based approach consistently rationalized the main structure-activity relationships within each ligand class, giving useful information for designing improved ligands.
Collapse
|
19
|
Huang T, Ji X, Wu W, Liang F, Cao S. Metal-free one-pot sequential direct diarylation of pyrazolin-5-ones with diaryliodonium salts. RSC Adv 2015. [DOI: 10.1039/c5ra14368c] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A novel and efficient one-pot sequential C4-diarylation of pyrazolin-5-ones with diaryliodonium salts at room temperature in the absence of a metal catalyst was reported.
Collapse
Affiliation(s)
- Tao Huang
- Shanghai Key Laboratory of Chemical Biology
- School of Pharmacy
- East China University of Science and Technology (ECUST)
- Shanghai 200237
- China
| | - Xinfei Ji
- Shanghai Key Laboratory of Chemical Biology
- School of Pharmacy
- East China University of Science and Technology (ECUST)
- Shanghai 200237
- China
| | - Wei Wu
- Shanghai Key Laboratory of Chemical Biology
- School of Pharmacy
- East China University of Science and Technology (ECUST)
- Shanghai 200237
- China
| | - Fang Liang
- Shanghai Key Laboratory of Chemical Biology
- School of Pharmacy
- East China University of Science and Technology (ECUST)
- Shanghai 200237
- China
| | - Song Cao
- Shanghai Key Laboratory of Chemical Biology
- School of Pharmacy
- East China University of Science and Technology (ECUST)
- Shanghai 200237
- China
| |
Collapse
|
20
|
Base initiated aromatization/CO bond formation: a new entry to O-pyrazole polyfluoroarylated ethers. Tetrahedron Lett 2014. [DOI: 10.1016/j.tetlet.2014.09.129] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Caroff E, Meyer E, Treiber A, Hilpert K, Riederer MA. Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y12 antagonists for inhibition of platelet aggregation. Bioorg Med Chem Lett 2014; 24:4323-31. [DOI: 10.1016/j.bmcl.2014.06.070] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2014] [Revised: 06/20/2014] [Accepted: 06/23/2014] [Indexed: 10/25/2022]
|
22
|
Bach P, Antonsson T, Bylund R, Björkman JA, Österlund K, Giordanetto F, van Giezen JJJ, Andersen SM, Zachrisson H, Zetterberg F. Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283. J Med Chem 2013; 56:7015-24. [DOI: 10.1021/jm400820m] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Peter Bach
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| | - Thomas Antonsson
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| | - Ruth Bylund
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| | - Jan-Arne Björkman
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| | - Krister Österlund
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| | - Fabrizio Giordanetto
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| | - J. J. J. van Giezen
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| | - Søren M. Andersen
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| | - Helen Zachrisson
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| | - Fredrik Zetterberg
- CVGI Medicinal Chemistry, ‡CVGI Bioscience, and §CVGI iMED Project Management, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
| |
Collapse
|